The proposed partnership between Charles Drew University (CDU) and UCLA Jonsson Cancer Center seeks to """"""""Eliminate Cancer Health Disparities in Minority and Underserved Populations"""""""". This objective will continue to strengthen the CDU cancer research and training infrastructure by enhancing the participation of minority students, fellows and faculty engaged in Cancer Research, Training, and Cancer Outreach. The partnership will continue to recruit new faculty with career focus in cancer research, education or outreach. Likewise, UCLA and the investigators in the JCCC will have the important opportunity to address, issues related to the unequal burden of cancer in minority populations. The partnership developed during our U56 funding has made a significant impact on our ability to develop strong pilots and partnership programs. A key new and important addition to our U54 program is the development of strong Cancer Outreach Program and Projects. Thereby, we will train more minority investigators addressing issues in cancer research, education, training and outcome in our communities. In view of the rapidly changing demographics of Los Angeles and the state of California, the CDU-UCLA Partnership is ideally situated and will have an opportunity to have a positive impact on reducing cancer incidence and improving survival in minority and underserved populations. The overarching goals of the CDU-UCLA Cancer Partnership Program are to significantly increase the number of minority scientists in cancer research and to enhance the cancer outreach programs at CDU to address significant disparities in cancer among minority populations. Supported and implemented by an Administrative Core, Planning and Evaluation Core, and Developmental Core, the basic program components are 1) research projects;2) the mentoring of students and junior investigators;3) the training seminar series;4) enhance CDU's integrated clinical and tissue biorepository data base on minority suubjects;5) enhance community participation;6) improve our clinical trials resource;and 7) increase faculty recruitment. We plan to submit 2 full projects and 2 pilot projects.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
3U54CA143931-04S1
Application #
8530618
Study Section
Special Emphasis Panel (ZCA1-SRLB-D (O2))
Program Officer
Moten, Carmen P
Project Start
2009-09-29
Project End
2014-08-31
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
4
Fiscal Year
2012
Total Cost
$179,916
Indirect Cost
$52,316
Name
Charles R. Drew University of Medicine & Science
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
785877408
City
Los Angeles
State
CA
Country
United States
Zip Code
90059
Wu, Y; Vadgama, J V (2017) Androgen Receptor as a Potential Target for Treatment of Breast Cancer. Int J Cancer Res Mol Mech 3:
La, V; Fujikawa, R; Janzen, D M et al. (2017) Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy. NPJ Precis Oncol 1:
Wang, Piwen; Solorzano, Walter; Diaz, Tanya et al. (2017) Arctigenin inhibits prostate tumor cell growth in vitro and in vivo. Clin Nutr Exp 13:1-11
Wu, Yanyuan; Tran, Trinh; Dwabe, Sami et al. (2017) A83-01 inhibits TGF-?-induced upregulation of Wnt3 and epithelial to mesenchymal transition in HER2-overexpressing breast cancer cells. Breast Cancer Res Treat 163:449-460
Maxwell, Annette E; Young, Sandra; Moe, Emily et al. (2017) Understanding Factors that Influence Health Care Utilization Among Mixtec and Zapotec Women in a Farmworker Community in California. J Community Health :
Dong, Yunzhou; Wu, Yong; Cui, Mei-Zhen et al. (2017) Lysophosphatidic Acid Triggers Apoptosis in HeLa Cells through the Upregulation of Tumor Necrosis Factor Receptor Superfamily Member 21. Mediators Inflamm 2017:2754756
Brennen, W Nathaniel; Zhang, Baohui; Kulac, Ibrahim et al. (2017) Mesenchymal stem cell infiltration during neoplastic transformation of the human prostate. Oncotarget 8:46710-46727
Kiyohara, M H; Dillard, C; Tsui, J et al. (2017) EMP2 is a novel therapeutic target for endometrial cancer stem cells. Oncogene 36:5793-5807
Wu, Yong; Yu, Xiaoting; Yi, Xianghua et al. (2017) Aberrant Phosphorylation of SMAD4 Thr277-Mediated USP9x-SMAD4 Interaction by Free Fatty Acids Promotes Breast Cancer Metastasis. Cancer Res 77:1383-1394
McGhee, Eva; Harper, Hill; Ume, Adaku et al. (2017) Elimination of Cancer Health Disparities through the Acceleration of HPV Vaccines and Vaccinations: A Simplified Version of the President's Cancer Panel Report on HPV Vaccinations. J Vaccines Vaccin 8:

Showing the most recent 10 out of 79 publications